SHL Telemedicine Ltd (SHLT) News

SHL Telemedicine Confirms Discussions Regarding a Possible Investment in its Israeli Activity

SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine...

SHL Telemedicine Expands Offering in Israel With Groundbreaking At-home Biomarker Blood Test

Users in Israel will be able for the first time in the world to perform an at-home Biomarker blood test guided by SHL’s medical team, following...

SHL Telemedicine Announces Official Launch of SmartHeart® D2C Membership in the US Following Successful Soft Launch

A revolutionary at-home 12-lead ECG service with 24/7 cardiologist review and telehealth service now fully available in the US. SHL Telemedicine...

US Index Futures See Gains, Oil Prices Dip

U.S. index futures displayed positive performance in pre-market trading on Wednesday, with S&P 500 aiming...

SHL Announces Full-Year 2023 Results - Stable Revenue Growth Alongside Groundbreaking Clinical Milestones

SHL Telemedicine Ltd. (NASDAQ: SHLT; SIX Swiss Exchange: SHLTN) ("SHL" or the "Company"), a leading provider and developer of advanced personal...

Imperial College London Study Shows Groundbreaking Final Results for SHL Telemedicine’s SmartHeart® in Post-ACS Patient Care

Groundbreaking Study reveals a 76% drop in hospital readmissions and a 41% decrease in Emergency Department...

SHL Telemedicine’s SmartHeart® Technology Triumphs in US Army Project Convergence – Capstone 4 Experiment

SHL’s SmartHeart portable 12-lead ECG technology successfully participated in the U.S. Army’s Project Convergence – Capstone 4 experiment...

SHL Telemedicine: Invitation to Conference Call Presenting Annual Results 2023

SHL Telemedicine Ltd. (SIX Swiss Exchange: SHLTN; NASDAQ: SHLT) ("SHL” or the “Company”), a leading provider and developer of advanced personal...

SHL Telemedicine reçoit une recommandation d’achat avec un objectif de prix de 11,00 dollars

Une importante société d’analyse financière propose un objectif de cours à deux chiffres pour SHL Telemedicine, la positionnant comme une...

SHL Telemedicine Receives Buy Rating with $11.00 Price Target

A leading equity research firm provides a double-digit price target for SHL Telemedicine, positioning it as an undervalued opportunity...

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]

Imperial College London TELE-ACS Clinical Trial Results, Using SHL Telemedicine’s SmartHeart® Technology, to Be Presented at ACC 24

The selection of the TELE-ACS trial results for presentation at ACC 24 highlights the pioneering achievements of Imperial College London and SHL...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form SC 13D - General statement of acquisition of beneficial ownership